Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Investing

Nutura Organic Ltd – Term Sheet to commence Pilot Study

by admin May 14, 2024
May 14, 2024
Nutura Organic Ltd – Term Sheet to commence Pilot Study

The Board of BPH Global Ltd (ASX: BP8) (Company) announces that the Company has entered into a legally binding Term Sheet (Term Sheet) with Australian-based company Nutura Organic Ltd (Nutura) for the purchase of adult milk formula to enable the Company to undertake a pilot study in China.

Highlights

Purchase of adult milk formula to commence pilot study in ChinaProposed development of adult milk formula products infused with TCM ingredients including sialic acid and nutraceuticals extracted from raw birds’ nest and seaweedFocus on sales and distribution in China

Nutura is a Melbourne-based company which produces a range of nutrition products made exclusively from Australian sourced milk including its GB-compliant product ‘Adult 60+ Milk Formula’ (Adult Milk Formula). Nutura is interested in expanding its product and distribution footprint throughout China. “GB compliant” is a reference to a product which has passed the product testing protocols and procedures prescribed by the National Standards of the People’s Republic of China.

As part of it continuing focus on opportunities to purchase or produce food products which deliver Traditional Chinese Medicine (TCM)-based outcomes, the Company is keen to undertake a pilot program in China to test the market for the sale and distribution of Nutura’s Adult Milk Formula and the opportunities to infuse that formula with TCM-based ingredients including sialic acid and nutraceuticals extracted from raw birds’ nest and seaweed (Pilot Study).

By committing to purchase an initial quantity of the Adult Milk Formula, the Company can commence a pilot study in China to determine the feasibility and commerciality of selling the Adult Milk Formula infused with TCM-based ingredients in China, including:

The cost of shipping the Adult Milk Formula to China and clearing Chinese customs procedures and protocols;The cost of obtaining the TCM-based ingredients, either in Australia or China, and infusing those ingredients into the Adult Milk Formula;The cost of delivery of the Adult Milk Formula to retail outlets; andThe level of consumer demand.

Term Sheet

Key terms of the Term Sheet are as follows:

Product: Adult Milk Formula.Quantity and Price: 3,500 units at an aggregate purchase price of approximately AUD35,000, after a rebate provide by Nutura to support marketing and promotional activities associated with the Pilot Study (Purchase Order)Nutura to ensure that the Adult Milk Formula is GB compliant.The term of the Term Sheet is valid until completion of each of the Company’s and Nutura’s obligations regarding the Purchase OrderFuture Activities: Nutura and the Company will continue to discuss commercial opportunities for the supply of Nutura’s products in the Chinese markets for their mutual commercial benefit with a focus on the Adult Milk Formula infused with TCM-based ingredients and leveraging the Company’s sales and distribution network in China.

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Top 10 Cryptocurrencies in 2024
next post
Steppe Gold Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with Proposed Transaction with Boroo Gold and Boroo Singapore

Related Posts

Prismo Metals Updates Exploration at Hot Breccia

February 28, 2025

Excellent Metallurgical Results at Hotinvaara Enhance Entire Pulju...

October 23, 2024

Gold Price Breaks US$2,900 as Tariff Turmoil Boosts...

February 11, 2025

Exclusive Interview with Alvopetro Energy CEO Corey Ruttan

November 16, 2024

Radiopharm Theranostics Completes A$70 Million Placement

June 28, 2024

Appendix 4D and Half Yearly Accounts

February 27, 2025

5 Best-performing Junior Copper Stocks on the TSXV...

October 25, 2024

Big Pharma Stocks Eli Lilly, AbbVie and Pfizer...

November 4, 2024

E-Power Resources Inc. Announces Closing of a Third...

November 20, 2024

5 Biggest Pharmaceutical ETFs in 2024

May 30, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Market Maker Manipulation; Oops, They Did It Again!

      May 14, 2025
    • 50% of S&P 500 Stocks Just Turned Bullish – What Happens Next?

      May 14, 2025
    • Bullish Breadth Improvement Suggests Further Upside For Stocks

      May 14, 2025
    • Tariff Tensions Ease, Nasdaq Soars — But is SMH the Emerging Leader?

      May 14, 2025
    • Lawsuit tracker: New resistance battling Trump’s second term through onslaught of lawsuits taking aim at EOs

      May 14, 2025

    Categories

    • Business (926)
    • Investing (2,165)
    • Politics (2,682)
    • Stocks (1,008)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved